Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harris A Ahmad

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Gastroenterology Report|September 13, 2015
The 2 + 1 paradigm: an efficient algorithm for central reading of Mayo endoscopic subscores in global multicenter phase 3 ulcerative colitis clinical trialsHarris A Ahmad, Klaus Gottlieb, Fez Hussain
Rheumatology (Oxford, England)|December 11, 2019
Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trialsEdward C Keystone, Harris A Ahmad, Yusuf Yazici, et al.
BMC Rheumatology|April 14, 2022
Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE studyPatrick Durez, Rene Westhovens, Femke Baeke, et al.
Journal of Clinical Medicine|July 2, 2020
Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid ArthritisYannick Degboé, Michael Schiff, Michael Weinblatt, et al.
Advances in Therapy|July 7, 2019
Determining MRI Inflammation Targets When Considering a Rheumatoid Arthritis Treat-to-Target Strategy: Results of a Randomized, Placebo-Controlled TrialHarris A Ahmad, Joshua F Baker, Mikkel Østergaard, et al.
Arthritis Research & Therapy|December 8, 2018
Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trialVibeke Strand, Evo Alemao, Thomas Lehman, et al.
Rheumatology International|May 2, 2020
Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritisPhilip J Mease, Iain B McInnes, Vibeke Strand, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 2, 2018
Predictors of pneumonia on routine chest radiographs in patients with COPD: a post hoc analysis of two 1-year randomized controlled trialsDavid B Rubin, Harris A Ahmad, Michael O'Neal, et al.
Annals of the Rheumatic Diseases|April 23, 2013
Measurement error in the assessment of radiographic progression in rheumatoid arthritis (RA) clinical trials: the smallest detectable change (SDC) revisitedV Navarro-Compán, D van der Heijde, Harris A Ahmad, et al.
Intestinal Research|April 19, 2023
Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directionsHarris A Ahmad, James E East, Remo Panaccione, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Gastroenterology Report|September 13, 2015
The 2 + 1 paradigm: an efficient algorithm for central reading of Mayo endoscopic subscores in global multicenter phase 3 ulcerative colitis clinical trialsHarris A Ahmad, Klaus Gottlieb, Fez Hussain
Rheumatology (Oxford, England)|December 11, 2019
Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trialsEdward C Keystone, Harris A Ahmad, Yusuf Yazici, et al.
BMC Rheumatology|April 14, 2022
Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE studyPatrick Durez, Rene Westhovens, Femke Baeke, et al.
Journal of Clinical Medicine|July 2, 2020
Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid ArthritisYannick Degboé, Michael Schiff, Michael Weinblatt, et al.
Advances in Therapy|July 7, 2019
Determining MRI Inflammation Targets When Considering a Rheumatoid Arthritis Treat-to-Target Strategy: Results of a Randomized, Placebo-Controlled TrialHarris A Ahmad, Joshua F Baker, Mikkel Østergaard, et al.
Arthritis Research & Therapy|December 8, 2018
Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trialVibeke Strand, Evo Alemao, Thomas Lehman, et al.
Rheumatology International|May 2, 2020
Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritisPhilip J Mease, Iain B McInnes, Vibeke Strand, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 2, 2018
Predictors of pneumonia on routine chest radiographs in patients with COPD: a post hoc analysis of two 1-year randomized controlled trialsDavid B Rubin, Harris A Ahmad, Michael O'Neal, et al.
Annals of the Rheumatic Diseases|April 23, 2013
Measurement error in the assessment of radiographic progression in rheumatoid arthritis (RA) clinical trials: the smallest detectable change (SDC) revisitedV Navarro-Compán, D van der Heijde, Harris A Ahmad, et al.
Intestinal Research|April 19, 2023
Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directionsHarris A Ahmad, James E East, Remo Panaccione, et al.
Pageof 3